WHAT WE DO? WE SELL OPTIONS FOR INCOME. WE USE THAT INCOME TO BUY DIVIDEND GROWTH STOCKS!
CHECK OUR TRADES ON OUR FACEBOOK PAGE OR HERE.


Johnson & Johnson boosts prices on top-selling drugs

  • Joining a number of other drugmakers this month, Johnson & Johnson (NYSE:JNJ) raised prices on about two dozen prescription drugs today, including top sellers Stelara (for psoriasis), Zytiga (for prostate cancer) and blood thinner Xarelto.
  • Most increases were in the 6-7% range, Reuters notes.

  • The company says average list price increase on its drugs will be 4.2% this year, but it expects net price it receives to drop after rebates and discounts. It says it doesn’t plan to raise prices on any more drugs this year.

  • Shares are down 0.4% after hours.

Source: Seeking Alpha





Leave a Reply

Your email address will not be published. Required fields are marked *